ArticleGut2001
Soluble E-cadherin is a valid prognostic marker in gastric carcinoma.
Article in Gut, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 88 citations in OpenAlex.
- Soluble E-cadherin-CXCL1-CXCR2 axis as a therapeutic vulnerability in inflammatory breast cancer brain metastasis.Neuro-oncology · 2026Article
- TMEM52B-derived peptides inhibit generation of soluble E-cadherin and EGFR activity to suppress colon cancer growth and early metastasis.Journal of translational medicine · 2025Article
- Tumor necroptosis-mediated shedding of cell surface proteins promotes metastasis of breast cancer by suppressing anti-tumor immunity.Breast cancer research : BCR · 2023Article
- Proteolytic Landscapes in Gastric Pathology and Cancerogenesis.International journal of molecular sciences · 2022Review
- Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer.Anticancer research · 2021Article
- Potential value of circulatory microRNA10b gene expression and its target E-cadherin as a prognostic and metastatic prediction marker for breast cancer.Journal of clinical laboratory analysis · 2021Article
- E-Cadherin Protein as a Potential Marker for Gastric Cancer and Its Association withReports of biochemistry & molecular biology · 2019Article
- Patients with advanced oral squamous cell carcinoma have high levels of soluble E-cadherin in the saliva.Medicina oral, patologia oral y cirugia bucal · 2017Article
- The extracellular domain of E cadherin linked to invasiveness in colorectal cancer: a new resistance and relapses monitoring serum-bio marker?Journal of cancer research and clinical oncology · 2017Article
- A three-miRNA signature as promising non-invasive diagnostic marker for gastric cancer.Molecular cancer · 2015Article
- Stem cells in gastric cancer.World journal of gastroenterology · 2015Review
- Genes Regulating Epithelial Polarity Are Critical Suppressors of Esophageal Oncogenesis.Journal of Cancer · 2015Review
- Increased SNAIL expression and low syndecan levels are associated with high Gleason grade in prostate cancer.International journal of oncology · 2014Article
- Levels of soluble E-cadherin in breast, gastric, and colorectal cancers.BioMed research international · 2014Review
- E-cadherin and gastric cancer: cause, consequence, and applications.BioMed research international · 2014Review
- Biomarkers for predicting future metastasis of human gastrointestinal tumors.Cellular and molecular life sciences : CMLS · 2013Review
- Soluble Neural-cadherin as a novel biomarker for malignant bone and soft tissue tumors.BMC cancer · 2013Article
- Cleavage of transmembrane junction proteins and their role in regulating epithelial homeostasis.Tissue barriers · 2013Review
- How echinoccocosis affects potential cancer markers in plasma: galectin-3, sN-cadherin and sE-cadherin? A preliminary report.Diagnostic pathology · 2012Article
- Soluble E-cadherin: more than a symptom of disease.Frontiers in bioscience (Landmark edition) · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer remains a major cause of cancer mortality globally but no good prognostic tumour marker is available. Soluble fragment of E-cadherin protein has been reported to increase in the sera of patients with cancer and recently was found to be elevated in 67% of patients with gastric cancer.
aimsTo investigate if serum soluble E-cadherin is a valid prognostic marker in gastric cancer.
methodsConcentrations of soluble E-cadherin from 116 patients with histologically confirmed gastric adenocarcinoma and 40 healthy subjects were measured using an immunoenzymometric method with a commercially available sandwich ELISA kit based on monoclonal antibodies.
resultsThe logarithm of the means of soluble E-cadherin concentration was significantly higher in patients with gastric cancers (mean 3.85 (SD 0.28)) than in healthy subjects (3.71 (0.18)) (p=0.001), and in palliative/conservatively treated cancers (3.91 (0.35)) than in operable cancers (3.78 (0.19)) (p=0.015). The logarithm of the concentrations correlated with tumour size (p=0.032) and carcinoembryonic antigen concentrations (p=0.001). The cut off value calculated from discriminant analysis on operability and inoperability/palliative treatment was 7025 ng/ml. Soluble E-cadherin concentrations higher than this cut off value predicted tumour (T4) depth invasion (p=0.020, confidence interval (CI) 1.008-1.668) and palliative/conservative treatment (p=0.023, CI 1.038-2.514). In contrast, the relative risks for lymph node (N2) metastasis, distant metastasis, and stage III/IV disease were 1.41, 1.33, and 1.55 respectively, despite not reaching statistical significance.
conclusionSerum soluble E-cadherin is a potential valid prognostic marker for gastric cancer. A high concentration predicts palliative/conservative treatment and T4 invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.